March 30, 2012Open Access
View Full PaperDeterminants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy
Structured PICO
What are the determinants of residual cardiovascular risk in coronary patients treated with statin therapy?
P
Population
9,251 coronary patients with low-density lipoprotein cholesterol <130 mg/dL with complete on-treatment 1-year lipid data from the Treating to New Targets (TNT) study
I
Intervention
Atorvastatin 80 mg/d (high-dose statin)
C
Comparator
Atorvastatin 10 mg/d (low-dose statin)
O
Outcome
Major cardiovascular events (composite of coronary death, nonfatal myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke)composite
In statin-treated secondary prevention patients, residual cardiovascular risk is driven by both lipid-related factors like baseline apolipoproteins and nonlipid factors including BMI, smoking, hypertension, and diabetes.
Abstract
BACKGROUND: Cardiovascular events occur among statin-treated patients, albeit at lower rates. Risk factors for this "residual risk" have not been studied comprehensively. We aimed to identify determinants of this risk above and beyond lipid-related risk factors. METHODS AND RESULTS: A total of 9251 coronary patients with low-density lipoprotein cholesterol <130 mg/dL randomized to double-blind atorvastatin 10 or 80 mg/d in the Treating to New Targets (TNT) study had complete on-treatment 1-year lipid data. Median follow-up was 4.9 years. The primary end point was major cardiovascular events (n=729): coronary death, nonfatal myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. Multivariable determinants of increased risk were older age (adjusted hazard ratio aHR, 1.13 per 1 SD 8.8 years; 95% confidence interval CI, 1.04-1.23), increased body mass index (aHR, 1.09; 95% CI, 1.02-1.17 per 4.5 kg/m(2)), male sex (aHR, 1.33; 95% CI, 1.07-1.65), hypertension (aHR, 1.38; 95% CI, 1.17-1.63), diabetes mellitus (aHR, 1.33; 95% CI, 1.11-1.60), baseline apolipoprotein B (aHR, 1.19; 95% CI, 1.11-1.28 per 19 mg/dL), and blood urea nitrogen (aHR, 1.10; 95% CI, 1.03-1.17 per 4.9 mg/dL), in addition to current smoking, prior cardiovascular disease, and calcium channel blocker use. Determinants of decreased risk were high-dose statin (aHR, 0.82; 95% CI, 0.70-0.94), aspirin use (aHR, 0.67; 95% CI, 0.56-0.81), and baseline apolipoprotein A-I (aHR, 0.91; 95% CI, 0.84-0.99 per 25 mg/dL). On-treatment 1-year lipids or apolipoproteins were not additionally associated with risk in multivariable models. Known baseline variables performed moderately well in discriminating future cases from noncases (Harrell c index=0.679). CONCLUSIONS: Determinants of residual risk in statin-treated secondary prevention patients included lipid-related and nonlipid factors such as baseline apolipoproteins, increased body mass index, smoking, hypertension, and diabetes mellitus. A multifaceted prevention approach should be underscored to address this risk. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT00327691.